PRISMA-CHM 2020:中药系统评价报告规范扩展
针对中药系统评价报告质量不佳、干预措施与选方依据报告不充分的问题,中医临床专家、方法学家、流行病学家和编辑共同制定了PRISMA-CHM 2020扩展。该扩展通过注册、文献回顾、共识会议、三轮德尔菲调查和定稿等流程完成,在PRISMA清单基础上引入中医证候概念和中药干预特征,共纳入24个条目(含子条目),涉及标题、结构化摘要、原理、目的、纳入标准、数据条目、结果综合、附加分析、研究特征、证据总结和结论等,并提供示例与解释,旨在提升中药系统评价的报告质量。
要点
- PRISMA-CHM 2020为中药系统评价提供24个条目(含子条目)的报告清单。
- 清单新增中医证候概念与中药干预特征,强调报告选方依据。
- 制定过程包括注册、文献回顾、共识会议、三轮德尔菲调查和定稿。
核心结论
- PRISMA-CHM 2020旨在改善中药系统评价的报告质量。
研究设计与样本
- 由中医临床专家、方法学家、流行病学家和编辑组成小组,通过注册、文献回顾、共识会议、三轮德尔菲调查和定稿等流程制定。
主要发现
- 在PRISMA清单基础上引入中医证候概念和中药干预特征。
- 清单共纳入24个条目(含子条目),涉及标题、结构化摘要、原理、目的、纳入标准、数据条目、结果综合、附加分析、研究特征、证据总结和结论等。
- 提供示例与解释。
关键数值与推荐
- 24个条目(含子条目)涉及标题(1)、结构化摘要(2)、原理(3)、目的(4)、纳入标准(6)、数据条目(11)、结果综合(14、21)、附加分析(16、23)、研究特征(18)、证据总结(24)和结论(26)。
临床怎么用
- 中药系统评价作者可参照PRISMA-CHM 2020清单报告研究,尤其注重中药干预措施和选方依据的报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chinese Herbal Medicines (CHM) are the most common interventions of traditional Chinese medicine (TCM), typically administered as either single herbs or formulas. Systematic reviews (SRs) are essential references for evaluating the efficacy and safety of CHM treatments accurately and reliably. Unfortunately, the reporting quality of SRs with CHM is not optimal, especially the reporting of CHM interventions and the rationale of why these interventions were selected. To address this problem, a group of TCM clinical experts, methodologists, epidemiologists, and editors has developed a PRISMA extension for CHM interventions (PRISMA-CHM) through a comprehensive process, including registration, literature review, consensus meeting, three-round Delphi survey, and finalization. The PRISMA checklist was extended by introducing the concept of TCM Pattern and the characteristics of CHM interventions. A total of twenty-four items (including sub-items) are included in the checklist, relating to title (1), structured summary (2), rationale (3), objectives (4), eligibility criteria (6), data items (11), synthesis of results (14, 21), additional analyses (16, 23), study characteristics (18), summary of evidence (24), and conclusions (26). Illustrative examples and explanations are also provided. The group hopes that PRISMA-CHM 2020 will improve the reporting quality of SRs of CHM.
引用
- Zhang X, Tan R, Lam WC, et al. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020. PMID: 32907365. doi:10.1142/S0192415X20500639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。